Genprex, Inc. (GNPX) Stock Score, Valuation & Financial Research

Genprex, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for GNPX

Genprex, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 2.61. These figures are a research snapshot, not a buy or sell recommendation.

What Genprex, Inc. does

Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Genprex is a clinical-stage gene therapy company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and strategic financing to fund the research, development, and clinical testing of its gene-based therapy candidates for cancer and diabetes.

Products and services

  • The company is developing gene therapy candidates, including Reqorsa (oncoprex) for cancer treatment and a gene therapy program for Type 2 diabetes.

Customer types

Patients with cancer; Patients with diabetes.

Suppliers, materials and equipment

  • Contract Development and Manufacturing Organization (CDMO) — The company engages third-party contract manufacturing organizations for the scale-up and production of its gene therapy candidates; the specific supplier company is unnamed. Source

Business relationships and partnerships

  • The University of Texas MD Anderson Cancer Center — A sponsored research agreement to study biomarkers for the prediction of patient response to Reqorsa Gene Therapy. Source
  • University of Pittsburgh — Collaboration on species analyses for animal models and regulatory/clinical strategic planning. Source

Business strengths to evaluate

  • Proprietary gene therapy platform technology Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Need for substantial additional funding to continue operations Source
  • Dependence on third-party manufacturers and clinical research organizations Source

Sources: Company research source · The University of Texas MD Anderson Cancer Center · Contract Development and Manufacturing Organization (CDMO)

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

GNPX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.61
Market capitalization:
1.32M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -16.5M
Free cash flow:
USD -15.31M
Cash:
USD 15.15M
Total debt:
USD 0.00
EPS:
USD -158.78

What stands out

  • Free cash flow is USD -15.31M, negative for the stored period.
  • The balance sheet shows USD 15.15M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 15.15M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for GNPX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can GNPX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is GNPX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for GNPX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of GNPX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research GNPX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.